Mature markets – Maximising the molecule

Collectively the mature markets generate 59% of the total revenues but they are becoming more difficult places where to prosper. They are demanding better outcomes as a precondition for paying for new medicines. Financial pressures have played a part in hardening healthcare payers’ policies. Crushing demographic and epidemiological factors have compounded these economic woes.

Our report identifies four ways for pharma to offer more value without charging more or to prove that it can remove costs from another part of the healthcare system to make room for the higher prices it’s charging.

  • Plugging leaks in the care pathway;
  • collecting clinical and economic evidence of how medicines perform in the real world;
  • measuring how patients feel; and
  • developing companion diagnostics to let healthcare providers use precious resources more effectively.